@article{JTD34171,
author = {Chenxi Zhang and Lei Wang and Weimiao Li and Zhao Huang and Wenhao Liu and Peilong Bao and Yuanyang Lai and Yong Han and Xiaofei Li and Jinbo Zhao},
title = {Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {12},
year = {2019},
keywords = {},
abstract = {Background: Increasing evidence has shown the effectiveness of surgery for stage IV non-small cell lung cancer (NSCLC). Present study aims to summarize the experience of our institution in dealing with advanced NSCLC in the context of multimodality therapy including lung surgery.
Methods: Patients underwent surgical resection for stage IV NSCLC diagnosed before or during surgery from January 2014 to June 2017 at Tangdu Hospital were included in this study.
Results: There were 88 stage IV NSCLC patients enrolled in this study. Among them, 35 patients with pleural metastases, 18 with brain oligometastases, 25 with extra-brain oligometastases and 10 with multiple metastatic sites or organs. For primary lung tumor, almost all (86/88) were resected with R0. For metastatic lesions, 53 patients received curative local treatment and 9 patients with partial treatment. There were 62 patients received adjuvant treatment, 10 patients received no adjuvant treatment and 16 patients with missing data of adjuvant treatment. The median overall survival of patients was 31.72 months. The estimated 3-year OS was 42.2%. Patients with pleural metastases and brain oligometastases got better outcomes than the ones with extra-brain oligometastases and multiple metastases (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/34171}
}